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Multiple HPA Profiles in Endogenous Depression: 
Effect of Age and Sex on Cortisol and 
Beta-Endorphin 
H. Akil, R. F. Haskett, E. A. Young, L. Grunhaus, j. Kotun, 
V. Weinberg, J. Greden, and S. J. Watson 
We have previously shown that a number of depressed patients demonstrated a failure to 
suppress corticotrophic secretion, as measured by ~-Endorphin/[3-Lipotropin ([3-End/[?,-LPH 
levels), following dexamethasone challenge. The current study is an extension and replication 
of these findings, as well as an analysis of some of the biological variables which may contribute 
to the variance in [3-End/[3-LPH nonsuppression. We continue in observe a high rate of [3- 
End/fl LPH nonsuppression in depressed patients following dexamethasone; this escape at 
the pituitary level is even observed in a number of patients who demonstrate normal cortisol 
suppression. Advancing age, particularly in women, led to higher baseline cortisol, lower 
baseline [3-End/[3-LPH, and a greater likelihood of being a nonsuppressor on one or both 
measures. 
Introduction 
It is well established that a proportion of patients with 
endogenous depression hypersecrete cortisol and show el- 
evated plasma cortisol during both active and inactive cor- 
tisol secretory phases (Sachar 1967; Sachar et al 1970, 
i973; Carroll et al . . . . .  Pzom et ~,o.,. et l ' J O / i t ;  c _ L i  ill-I I l " ~ o c ,  f~.l..llJIIllr~"k'-- ~1 ,,11 
1967; Halbreich 1985). In addition to cortisol hypersecre- 
tion, as many as two-thirds of endogenously depressed 
patients also fail to suppress cortisol or show an early 
escape from the suppressive effects of 1 mg of dexameth- 
asone. Although both of these cortisol abnormalities are 
present in endogenously depressed patients, they do not 
necessarily occur in the same individual (Carroll et al 1976b, 
198 ! ). The work of Carroll and collaborators (1981) ini- 
tially suggested that this failure to suppress cortisol fol- 
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lowing dexamethasone challenge was specific to endoge- 
nous depression/melancholia. Many patients who meet 
Research Diagnostic Criteria (RDC) criteria for major de- 
pressive disorder but who do not meet the criteria for 
endogenous subtype, show no..rmal suppression of cortisol 
with dexamethasone (Carroll et al 1981, 1980; Bloan and 
Inuey 1980; Schlesser et al 1979). Limbic system dys- 
function is the hypothesized defect underlying both cortisol 
hypersecretion and dexamethasone nonsuppression. The 
presumed mechanism is increased release of corticotropin 
releasing ho..rmone (CRH) from the hypothalamus resulting 
in increased release of adrenocorticotropic hormone (ACTH) 
from the anterior pituitary and subsequent increased cor- 
tisol secretion from the adrenal (Carroll et al 1967a; Gold 
et al 1986). Although such a theory may explain the cor- 
tisol data, it should be remembered that there are a number 
of different levels of the hypothalamic pituitary adrenal 
axis (HPA) intervening between the brain and adrenal, and 
that each level may have regulatory mechanisms that mod- 
ify the signal transmission rather than transmit the signal 
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unchanged. In addition, the failure to suppress cortisol 
after dexamethasone involves feedback mechanisms at 
multiple levels of the HPA axis. Thus, it may reflect sev- 
eral abnormalities such as decreased sensitivity to the in- 
hibitory effects of dexamethasone, a change in set point 
for steroid inhibition, or even adrenal hypertrophy rather 
than an increased drive to secrete via increased CRH re- 
lease. Indeed, studies using CRH have suggested abnor- 
malities downstream from CRH secretion, either due to 
altered pituitary sensitivity or altered circulating levels of 
steroids (Gold et al 1986; Holsboer et al 1984; Young et 
al 1990). Thus, in attempting to understand the abnormal 
response to dexamethasone it is critical to explore multiple 
levels of the HPA axis examining both resting levels and 
responsiveness to the challenge. 
Studies focusing on pituitary regulation in depressed 
subjects have identified complex regulatory mechanisms. 
Many of these studies have measured either ACTH levels 
or 13-endorphin/13-1ipotropin levels (13-END/13-LPH). ACTH 
and 13-endorphin are synthesized from a common precursor 
that is packaged into the secretory granules of the anterior 
lobe corticotrophs prior to being processed. Thus, each 
granule contains equimolar amounts of the ACTH domain 
and the 13-END/t3-LPH domain. These two domains are 
then released equimolarly on secretory signals (Eipper and 
Mains 1990; Young and ALil 1985; Guillemin et al 1977). 
Thus, either ACTH measures, or 13-END/~-LPH measures 
in plasma, when properly characterized, can be used as 
indices for the activity of the anterior lobe corticotroph. 
Several investigators (Pfohl et al 1985; Kalin et al 1982; 
Risch 1982; Nasr et al I983) have reported that major 
depressive disorder (MDD) subjects who are Dexameth- 
asone Suppression Test (DST) nonsuppressors have shown 
elevated resting levels of either ACTH or [3-endorphin. 
Other investigators have failed to find such differences in 
resting ACTH or 13-endorphin levels between DST sup- 
pressors or nonsuppressors, or among DST suppressors, 
nonsuppressors, and normal controls (Fang et al 1981; 
Reus et a! !982; Matthews et a! !986). Some of the vari- 
ability in these studies may be contributed by differences 
in diagnostic subgroups, because most studies included all 
patients with MDD, regardless of whether they met criteria 
for endogenous subtype. When examining plasma ACTH 
or 13-END levels after dexamethasone challenge, the re- 
ports still show some disagreement; however, most groups 
agree that cortisol nonsuppressors demonstrate higher ACTH 
levels following dexamethasone as compared to cortisol 
suppressors (Pfohl et al 1985; Kalin et al 1982; Nasr et al 
1983; Reus et al 1982, 1983; Yerevanian et al 1983; Hols- 
boer et al 1983; Berger et al 1985). Only a few investi- 
gators report no difference in postdexamethasone ACTH 
among DST suppressors, DST nonsuppressors, and normal 
controls. (Fang et al 1981; Yerevanian and Woolf 1983). 
The failure to demonstrate differences in ACTH values 
following dexamethasone challenge between any de- 
pressed subgroups and normal controls has led Fang et al. 
(1981) to suggest a possible adrenal dysfunction in depres- 
sion, a suggestion that was lent some support by the report 
of Amsterdam et al (1985) showing an increased cortisol 
response to ACTH 1-24 infusion in MDD patients com- 
pared to normal subjects. What emerges from these studies 
is that more MDD patients appear to show abnormalities 
with feedback challenge (dexamethasone) than with mea- 
surements of resting levels, and, that there may be dys- 
regulation of the HPA axis at more than one level resulting 
from biological heterogeneity in the adaptation mecha- 
nisms used across levels of the HPA axis. 
A major difficulty faced in the studies of pituitary regu- 
lation in affective disease involves the definition of what 
constitutes a normal or abnormal peptide response to dexa- 
methasone challenge. If postdexamethasone peptide levels 
are averaged together for all subjects of a particular diag- 
nostic group, it may lead to failure to observe a significant 
postdexamethasone difference between MDD patients and 
psychiatric controls. This is caused hy the biological het- 
erogeneity within the MDD population as well as to sub- 
stantial interindividual variation of resting ACTH and ~- 
endorphin levels. For cortisol, when a cut-off criterion is 
employed to define suppression for an individual subject, 
such as in the standardized dexamethasone suppression test, 
30%-60% of the MDD endogenously depressed subjects 
emerge as nonsuppressors (Carroll et al 1981; Schlasser et 
al 1989; Matthews et a11986; Amsterdam et a11982; Stokes 
et al 1984; Copper et al 1983). Unfortunately, equivalent 
cut-off criteria are not easily established for either plasma 
ACTH or 13-END/13-LPH because of a number of problems, 
most prominently the variance in the peptide assays. To 
counter this problem, rather than looking at mean postdex- 
amethasone 13-endorphin levels across diagnostic groups, we 
have proposed two criteria to determine lack of suppression 
of plasma peptide levels. The first criterion uses the same 
concept of referent values that was employed for determin- 
ing the cortisol cut-off criterion. It simply consisted of a 
postdexamethasone 13-endorphin value larger than 2 
fmoles/ml. This referent cut-off value was used because over 
90% of our controls had postdexamethasone 13-endorphin 
levels below that level. We also proposed an aitemative 
strategy that used each subject as his or her own control 
(Matthews et al 1986). It involved the following method: 
four basal samples and four matched postdexamethasone 
samples are obtained for a given subject, and the mean and 
standard errors of the mean (SEM) for each set of samples 
is computed. In control subjects, dexamethasone sup- 
presses plasma I3-END/13-LPH levels such that there is no 
overlap of the means -4- SEM between the postdex and the 
predex samples. If this "overlap" criterion is used in MDD 
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patients, a number of them "fail to suppress", that is, ex- 
hibit overlapping standard errors of the predex and postdex 
means (Matthews et al 1986). This alternative approach uses 
an individual criterion of suppression and does not require 
an absolute cut-off. Neither of these criteria has been fully 
validated to date, nor is it clear that either one will represent 
the ultimate yardstick by which to define dexamethasone 
nonsuppression or "rex-abnormality" at the level of the pi- 
tuitary corticotmphs. Their theoretical advantages have been 
discussed previously (Matthews et al 1986). However, we 
need to determine empirically whether they continue to yield 
meaningful data vis-h-vis the HPA dysregulation in depres- 
sion. In general, we have favored the use of the "overlap" 
criterion because it depends exclusively on within subject 
comparisons, all carded out in one assay, and avoids inter- 
assay variability, which can be problematic in peptide mea- 
surements. Finally, it should be noted that a third measure 
was also used by our group (Meador-Woodruff et al 1987) 
in examining the relationship between dex~methasone ef- 
fect on B-endorphin and severity of depression. This mea- 
sure essentially depended on the ratio of postdex levels to 
predex [3-endorphin levels, for each individual patient. 
However, in a series of comparison's across ~-::ore tha~ I00 
,,,-,o--,--~,~"hi°"t~ ..;t has become app~ent tlmt the overlap ~,!d the ra- 
tio method lead to essentially identical conclusion~ (i.e., most 
subjects who have suppressed by 40% will have suppressed 
by the overlap criterion and vice versa). The feature that all 
three criteria share is that they attempt to gauge the corti- 
cotrophic response for each individual subject, rather than 
looking at group means. 
Using the overlap criterion, we have reported two major 
observations (1) over 50% of the MDD patients exhibit a 
[3-END/iB-LPH escape from dex at 4 PM, as compared to 
8%-11% in psychiatric controls, and (2) there is only 
partial concordance between an abnormal [3-END/[3-LPH 
response and an abnormal cortisol response to dexameth- 
asone. As a result, combining the two HPA tests led to a 
high rate of abnormality in the MDD patients (69%-72%) 
as compared to non-MDD psychiatric controls (8%-11%) 
(Matthews et al 1986). 
The purpose of the present study is three-fold: (1) to 
test the overlap criterion in a group of normal subjects, 
(2) to replicate in a separate patient group our previous 
report on the abnormal plasma [3-END/[B-LPH response to 
dexamethasone challenge in MDD subjects, and (3) to 
further investigate the possible sources of variance or het- 
erogeneity influencing HPA axis functioning of MDD pa- 
tients. Specifically, can we discriminate those patients likely 
to respond abaormally on the cortisol assay, the [3-END/[3- 
LPH assay, or both? In this study, we focused on factors 
such as the age and sex of the patients, as potentially 
important variables that determine patterns of abnormality 
in the HPA axis. 
Subjects and Methods 
Normal Controls 
Sixteen consenting nonsmoking, nonjogging, control sub- 
jects (7 men, 9 women), 20-68 years old, were recruited 
by advertisement for participation in this study. Subjects 
were required to be medication and alcohol free fer at least 
2 weeks prior to the study, verified by a urine drug screen. 
All subjects received a physical exam and laboratory blood 
work for evaluation of electrolytes, liver functions, he- 
matocratic/hemoglobin, and thyroid functions. All normal 
control subjects were screened for psychiatric illness by a 
structured interview, the SADS-L (Schedule for Affective 
Disorders and Schizophrenia-Lifetime). The studies were 
conducted on the Clinical Research Center at the Univer- 
sity of Michigan Hospital. 
Fatients 
The 34 patients for this new study were patients on the 
Clinical Studies Unit in the Depression Program of the 
Department of Psychiatry, University of Michigan Medical 
Center over a period of 4 years. These data have not been 
included in any previo~:sly published report. 
All patients ga',~ informed consent. After withdrawal 
from all medication, each completed a standard diagnostic 
evaluation. The assessment included two independent clin- 
ical interviews by a faculty psychiatrist and a psychiatry 
resident or a research fellow; a structured interview using 
the Schedule for Affective Disorders and Schizophrenia 
(SADS), co~:pleted by a separate clinician; family inter- 
views conducted by a social worker, seeking supplemental 
information about the clinical features and longitudinal 
course of the patient's disorder and family history ef psy- 
chiatric disorder; review of all previous medical records; 
and physical examination with clinical laboratory testing 
to identify any serious physical disorders. After comple- 
tion of the evaluation, relevant clinical and research per- 
sonnel assigned a consensual diagnosis to each patient 
using the RDC. 
Patients were excluded from the study if they were una- 
ble to remain medication free for 14 days, or if at the time 
of presentation, they were taking medication known to in- 
terfere with interpretation of the dexamethasone test (Car- 
roll 1985), were suffering from any serious physical illness, 
weighed less than 80% of ideal body weight, or were preg- 
nant. Twenty-one patients met criteria for MDD, definite or 
probable endogenous subtype. Among the remaining 13, 5, 
subjects had a diagnosis of mania and were analyzed sepa- 
rately; 8 :,,bjects did not meet criteria for affective disor- 
ders and were termed psychiatric controls (2 schizophren- 
ics, 4 schizoaffective, depressive type, 1 unspecified 
Iunctlonal psychosis and 1 "other psychiatric disorder"). 
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Clinical Ratings 
At the time of the study protocol, the treating psychiatrist 
completed a clinical rating of depressive symptoms using 
the 17-item Hamilton Depression Rating Scale (HDRS). 
All clinicians involved in the diagnostic procedure and 
completing clinical ratings are blind to the research lab- 
oratory data. Similarly, all laboratory assays are completed 
in the absence of any clinical information about th~ patient. 
As a further safeguard, all tubes are randomized and as- 
sayed without knowledge of the sample sequence during 
the experiment. 
Experimental Protocol 
All patients and controls were medication free for at least 
14 days before completing the experimental protocol. On 
Day 1, at 1:30 PM, an intravenous catheter was inserted 
and the subject remained at rest until all samples were 
collected. At 3:30 PM, following 2 hr of rest and adapta- 
tion, sampling began, and a total of 4 samples were taken 
at 20 min intervals (3:30 PM, 3:50 PM, 4:10 PM, and 4:30 
PM). The subjects were given oral dexamethasone at 11 
PM. Day 2 postdexamethasone sampling was identical to 
Day 1 sampling, with a catheter insertion at 1:30 PM and 
four samples drawn between 3:30 and 4:30 PM (Matthews 
et al 1986). 
Blood Collection 
Blood samples for the measurement of 13-END/13-LPH lev- 
els were collected in chilled EDTA-containing (Ethylene 
Diamine-Tetraacetate) vacutainers (BD Vacutainers Brand 
Becton-Dickinson). The samples immediately were chilled 
on ice and centrifuged at 4°C within 10 min. The plasma 
was then acidified with 0.5 ml in HCI and immediately 
stored at -70°C until extraction. 
Biochemical Assays: ~-END/fl-LPH, ACTH, 
I ~ ~ - - , ~ :  ~ ~ I 
I.., U !  ~ g~UE, 
1. Peptide Extraction for ACTH and fl-END/fl-LPH 
R/A. Plasma samples were extracted on Sep-Pak C~8 
cartridges prior to the radioimmunoassay (RIA) in 
order to co,~centaate the peptides within the limits 
of sensitivity of the assay and to remove nonspecific 
inhibitors of the RIA found in plasma. This ex,rac- 
tion nrocedure is rapid, requiring only minutes, and 
it yields over 95% recovery for 13-END, 13-LPH, 
ACTH, &ad proopiomelanocortin (POMC) (Cahill 
et al i983). Following this procedure ACTH and 13- 
END/13-LP:I ure assayed using the RIA methods 
described below. 
2. fl-END/fl-LPH RIA. The procedure for production 
of the antibody used in this assay has been detailed 
previously 0?¢atson 1982). The serum harvested from 
the rabbit named Brenda was selected for use in 
measurement of 13-END/13-LPH-like immunoreac- 
tivity in human plasma because it was determined 
to be "'- . . . . . .  at concentra- parucuta, ty sensitNc low "~ ' uf i a l
tions of antisera (1:20,000 to 1:100,000 final dilu- 
tion). At very high dilutions, the small population 
of antibodies exploited in the radioimmunoassay has 
high affinity for the antigen. The optimum final di- 
lution is 1:40,000. The serum is not crossreactive 
with alpha-END (13-END 1-16), gamma-END (13- 
END 1-17), 13-END 27-31 or des-tyrosine gamma- 
END (13-END 1-17). The antigenic determinants of 
the Brenda antiserum at 1:40,000 final dilution are 
primarily between positions 17 to 27 of the 13-END 
peptide, but there is also a modest carboxy-terminus- 
recognizing population. There is no crossreactivity 
at I IxM concentrations of [Met]Enk, [Leu]Enk, Dyn 
A, Dyn B, alpha-neoendorphin, N-acetyl dynor- 
phin, or a number of pituitary peptides of a nono- 
pioid nature (oLMSH, ACTH, ~/MSH). To maximize 
the sensitivity of the curve, disequilibrium incuba- 
tion is used. In this procedure, the antibody and the 
unknown samples or standards are incubated in a 
total volume per assay tube of 0.150 ml for 24 hr 
at 4°(2. The tracer is then added to 0.100 ml of RIA 
buffer (150 mmol/L Na phosphate buffer with 1% 
NaCI and 0.3% human serum albumin pH 8.2) 
bringing the total volume to 0.250 ml. The tubes 
are vortexed and agaip incubated at 4°C for over- 
night. Ihe assay is separated by immunoprecipita- 
tion with sheep antirabbit immunoglobulin G (IgG). 
We can detect reliably 0.5-1 fmole of i3-END/ 
13-LPH-like immunoreactivity per assay tube, with 
an ICso of 12 fmoles. We typically add the equiv- 
alent of 2 ml of extracted plasma/assay tube, allow- 
ing us to detect reliably values of 0.25-0.5 fmoles/ml 
of plasma. Each sample is run in triplicate, yielding 
less than 8% variability. Interassay variability within 
a given tracer is less than 10%. However, with sep- 
arate iodinations, intrassay variability can increase 
up to 17%, and the system needs recalibration. 
ACTH RIA. The antibody used for measuring ACTH 
in plasma was raised in rabbits, against synthetic 
ACTH coupled to thyroglobulin. Hence, this is a 
midportion antibody that recognizes full ACTH~_39 
but has little or no crossreactivity with smaller pep- 
tides derived biosynthetically from ACTH, includ- 
ing otMSH and corticotropin-like intermediate lobe 
peptide (CLIP, also known as ACTH18.39). Plasma 
samples were extracted on Sep-Pak C~8 cartridges 
prior to determination of ACTH immunoreactivity, 
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with nearly 100% extraction efficiency. The RIA 
was performed in a 0.15 mmoPL sodium phosphate 
buffer containing 0.10 mmol/L NaCI, 0.004 mmol/L 
EDTA, 0.02% sodium azide, 0. 1% polylysine at pH 
7.6. The antiserum was used at a final dilution of 
1:80,000 in the assay, and the radiotigand was '251- 
ACTHl.39. We can detect reliably 5 fmole of 
ACTH/assay tube with an IC5o of 50 fmoles. In- 
traassay variability is within 10%. 
4. Corticosteroid Assay. Plasma total corticosteroids 
Ccortisor') are measured by the competitive protein 
binding (CPB) technique of Pegg and Keane (1969) 
as modified by de la Pena and Goldzieher (1977). 
Plasma samples were extracted with ethanol rather 
than dichloromethane, and double rather than single 
aliquots of the ethanol extract were assayed. Sam- 
ples and cortisol standards were dissolved in etha- 
nol-saline prior to assay. The radioligand was 
[3H]cortisol, and Fuller's earth was used to absorb 
free cortisol. The overall sensitivity of this CPB 
method for plasma corticosteroids is 0.3 ~g/dl plasma. 
In the range of 3.0 I~g/dl to 10.0 I~g/dl (typical 
plasma ccrtisol concentrations), the assay has a pre- 
cision better than or equal to + 8.3%. ,'flue. intraas- 
say coefficient of variation is 2% and the interassay 
coefficient of variation is 7%. The method is not 
completely specific for cortisol, as it also measures 
other glucocorticoids and gonadal steroids in plasma 
to a small extent. In terms of their contribution to 
total plasma corticosteroids measured in this assay, 
the most significant of these noncortisol steroids are 
corticosterone, cortisone, and 11-deo~ycorfisol. 
5. Data Handling. Biochemical data (peptide and ste- 
roid individual values) and clinical data (age, sex, 
diagnosis, weight loss, Hamilton score, day of men- 
strual cycle, etc.) were all entered in a data base 
using dBase III, (Ashton-Tate) on an IBM-AT and 
interfacing with a more detailed clinical data base 
maintained by the Clinical Studies Unit on the main 
computer system at ,h°,,,,, ~T.~;,.,,,,,,,, o,,J;h' ,,,-f Michig.~ 
(MTS). RS-I (Bolt & Beranck and Newman, Inc., 
Boston, Mass.) was used for slafistical analysis in- 
cluding t-tests, correlation coefficients, and X 2 tests. 
R e s u l t s  
Dexamethasone Effect in Normal Controls 
The result~ of the study in normal controls are included 
in Table 1 and Figure 1. These data validate the overlap 
criterion in a nonpsychiatric population. The individual 
predex and postdex values are displayed to demonstrate 
the use of the criterion. Every subject shows mean post- 
dexamethasone values with a confidence limit (SEM) that 
falls below the confidence limits of the mean predexa- 
methasone values, that is, there is no overlap between the 
individual predexamethasone and postdexamethasone 
means. (For example, for Subject 7 the postdex higher 
limit is 2.86 + 0°08 = 2.94. His predex lowest limit is 
3.47 - 0.31 = 3.16. Because the lowest limit predex is 
higher than the highest limit postdex there is no overlap 
between the confidence limits of the two means, and the 
subject is termed a "suppressor"). Civen our operational 
definition, we would consider all these normal controls 
"suppressors." In addition, the entire group exhibits sig- 
nificantly decreased postdex values relative to predex (paired 
t test, p < 0.0001). 
Replication and Extension of Previous Results 
In the previous study, (Matthiews et al 1986) termed Study 
I, we reported our findings on a total of 47 MDD subjects 
from 3 centers (18 University of Michigan, 16 Henry Ford 
Hospital, and 13 Yale University), and 16 psychiawic con- 
trol patients (a combined pool from University of Michigan 
and from Yale University). The composition of patients 
in the present study (termed Study H) was summarized in 
the Methods section. 
The results of the current study (Study II) are sum- 
marized in Table 2, Panel B, using the criterion of"overlap 
between SEM" for the 13-END/I3-LPH. As mentioned above, 
each of the nomial control subjects showed a clear suppres- 
sion postdex using the overlap criterion. Furthermore, 6 
of 8 psychiatric controls suppressed 13-END/13-LPH secre- 
tion. Indeed, the psychiatric control group predex mean 
was 2.54 -4- 0.5 and the postdex mean was 0.75 +- 0.2, 
a significant treatment effect (paired t-test 2p = 0.008). 
Using the overlap criterion, 57% of the MDD patients 
failed to suppress, as )mpared to 25% of the psychiatric 
controls. The frequency of cortisol nonsuppression after 
dexamethasone was 33% in the MDD group and 0% in 
the control group (Interestingly, in our small sample of 
patients with a cu~,ent diagnosis of mama we obtained a 
~-'Y,~,v l~.t~ nfv. e-R"~NFI/f4-1--,-._ r  ~PI ' I  non~uppression but 20% cor- 
tisol nonsuppression). 
Table 2 also compares the results from the recent study 
with those of the subset of patients from our first report 
who were from the University of Michigan (Study I), using 
the overlap criterion. In general, Study II replicated Study 
I with remarkable closeness. The frequencies of 13-END/I3- 
LPH nonsuppression and cortisol nonsuppression in both 
the MDD and the psychiatric controls were quite com- 
parable. Over 50% of the MDD patients from either study 
are abnormal with the 15-END/13-LPH assay, whereas 33% 
are abnormal with the cortisol assay r,- ,-, ~ au,e 2, Panels A, 
B). The most prominent difference in the results from the 
two studies was the frequency with which cortisol and 13- 
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Table  1. Individual  Values  for  N o r m a l  Cont ro l s  
Subject Sex Age Predex 
!. M 24 3.34 ___ 0.76 
2. M 24 !.98 __ 0.18 
3. M 27 1.98 ± 0.23 
4. M 32 1.21 _+ 0.63 
5. M 40 1.79 ± 0.82 
6. M 60 
7. M 68 3.47 ___ 0.31 
8. F 20 0.90 ± 0.74 
9. F 26 1.99 -_- 0.15 
10. F 26 1.34 ± 0.33 
11. F 27 0.87 ± 0.14 
12. F 35 2.26 --- 0.13 
13. F 40 1.31 ± 0.18 
! 4  F 50 1.96 --- 0.22 
15. F 54 1.93 ± 0.05 
16. F 66 1.13 ± 0.15 
x _ SEM Male 2.16 ± 0.34 
Female 1.52 ___ 0.17 
All 1.80 ± 0.19 
13-Endorphin (fmoles/ml) Cortisol (l~g/dl) 
Postdex Predex Postdex 
Not Detectable (0.05) 
Not Detectable (0.05) 
Not Detectable (0.05) 
0.33 ± 0.23 
0.25 ± 0.08 
0.27 ___ 0.03 
2.86 ± 0.08 
0.05 - 0.01 
0.50 ± 0.17 
0.06 --- 0.01 
0.21 --- 0.05 
0.36 ± 0.19 
0.17 ± 0.01 
0.66 _ 0.6 
1.20 --- 0 2 3  
0.65 ± 0.21 
0.55 --- 0.38 
0.43 ± 0.12 
0.48 ± 0.18 
5.03 - 0.98 1.18 - 0.02 
4.33 ± 0.3 1.20 ± 0.04 
1.83 ± 0.17 0.80 --- 0.07 
1.88 ± 0.17 0.98 ± 0.1 
3.68 --- 0.61 1.13 ± 0.16 
6.50 ± 0.51 1.30 ± 0.05 
10.68 ± 0.33 2.53 - 0.34 
5.1 ± 0.64 0.93 ± 0.04 
7.1 ± 0.55 1.40 ± 0.10 
2.35 z 0.16 1.20 ± 0.07 
3.53 ± 0.38 1.73 ± 0.09 
2.98 - 0.18 0.88 ± 0.02 
5.43 ± 0.49 !.43 ± 0.09 
5.05 ± 0.60 2.98 ± 0.14 
4.65 ± 0.aS 0.75 ± 0.06 
3.25 -4- 0.32 0.33 ± 0.25 
4.85 ± 1.16 1.30 ± 0.20 
4.38 ± 0.49 1.29 ± 0.25 
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Figure  1. Endocr ine  prof i les  f r o m  
c o m b i n e d  Study I and  S tudy  I I ,  wi th  
Pre  Dex  and Pos t  D e x  va lues  fo r  nor-  
mal  controls ,  psych ia t r i c  cont ro ls ,  
and M D D  subjects  wi th  H a m i l t o n  
scores  > 15. 
Table  2. Dex Effect  in UM :5tuales | and  ii: Rate  ot  N o n - S u p p r e s s i o n  
A: Study I 
n 13-END Cort Either n 
B: Study II 
13-END Con Either n 
C: Study I & II 
13-END Cort Either 
Normal 4 0% 0% 0% 16 
controls 0/4 0/4 0/4 
Psych 8 13% 0% i 3% 8 
controls 1/8 0/8 1/8 
All MDD 18 50% 33% 72% 21 
patients 9/18 6/18 13/18 
MDD Pts 17 53% 29% 71% 14 
HDRS > 15 9/17 5/17 12/17 
0% 0% 0% 20 0% 0% 0% 
O/16 O/i 6 O/16 O/20 O/20 O/20 
25% 12% 25% 16 18% 6% 18% 
2/8 1/8 2/8 3/16 1/16 3/16 
57% 33% 57% 39 54% 33% 64% 
12/21 7/21 12/21 21/39 13/39 25/39 
57% 42% 57% 31 55% 35% 65% 
8/14 6/14 8/14 17/31 11/31 20/31 
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END/13-LPH nonsuppression occurred in the same pa- 
tients. In Sandy !, a number of patients had only one 
abnormality, but a combination of the two measures in- 
dicated 70% of patients showed nonsuppression of either 
13-END/13-LPH or cortisol after dexamethasone. In Study 
II, every subject who was 13-END/fl-LPH abnormal was 
also cortisol abnormal. Thus, combining the two tests gave 
no increment over measuring 13-END/13-LPH alone. The 
reason for this discrepancy is unclear. Nevertheless, Study 
II confirmed the major conclusions of Study I: (1) The I~- 
END/13-LPH measures, as used with the overlap criterion, 
reveals a significant level of abnormality in the MDD pa- 
tients in contrast to other psychiatric subjects, (2) the B- 
END/13-LPH assay demonstrates at least as a high a rate 
of escape from dexamethasone as the cortisol assay, and 
(3) there is considerable heterogeneity in the MDD pop- 
thatlun, in that a substantial number of significantly de- 
pressed patients (HDRS > 15) respond normally on one 
or both measures. 
C O M P A R I S O N  BETWEEN A C T H  AND p-END/p-LPH RE.  
SPONSE. It could be suggested that the dissociation be- 
tween cortisol and 13-END/13-LPH responses to dexameth- 
asone observed in the first study is caused by different 
effects of dexamethasone on the secretion of ACTH and 
i3-END/13-LPH, rather than differences in the responses 
of the pituitary and adrenal. To test this possibility, we 
examined the ACTH and 13-END/13-LPH responses to dex- 
amethasone ,'_n a small subgroup of subjects. The results 
are summarized in Table 3. As can be seen using the 
"overlap criteria," there is complete concordance between 
the two assays---not necessarily in absolute levels, but in 
categofizi.ng a subject as demonstrating normal or abnor- 
mal suppression. Examining both ACTH and 13-END/13- 
LPH responses to dexamethasone, we found that there was 
complete concordance between assays ft., ,tch pa~c.nt. 
The 13E RIA was used as ~ e  primary measure of pituitary 
tone because of its high sensitivity relative to the ACTH 
RIA (0.25 fmoles/ml versus 2 fmoles/ml). Such sensitivity 
is particularly critical when looking at nightly pestdex 
values, which can be very low. 
COMBINED ANALYSIS OF UNIVERSITY OF M I C H I G A N  
SUBJECTS FROM STUDIES l & !I).  Having shown that the 
results from both University of Michigan studies are highly 
consistent, we have decided to combine them for further 
analyses (total MDD, n = 39; MDD with HDRS > 15, 
n = 31; total psychiatric controls, n = 16). Because of 
their small number, patients with a diagnosis of mania 
were not inciuded in this combined analysis. 
The last column of Table 2 (Panel C) summarizes the 
incider~ce of nonsuppression across the two studies or 
both 13-END/~-LPH and cortisol measures for the com- 
bined groups. As can be seen, the MDD patients exhibit 
a 54% rate of abnormality in 13-END/13-LPH measures, 
33% on cotiisol measmes, mid 64% on either. MDD pa- 
tients with Hamilton scores greater than 15 had slightly 
higher rates. The psychiatric controls have a combined 
rate of abnormality of 18% and the normal controls 0%. 
Because of the larger numbers resulting from the com- 
bination of samples, we can now average absolute val- 
ues of peptides with less concern for possible interassay 
differences. Figure 1 summarizes these results focusing 
on the MDD patients with Hamilton scores greater than 
15. This summary compares these patients (n = 31) with 
the 16 control subjects from Study II, and 16 psychiatric 
controls from Studies I and II. Dexamethasone causes a 
significant reduction in both 13-END/13-LPH and cortisol 
Table 3. Relationship between ACTH and 13-End/13-LPH Assays (+)  Means Escape and ( - )  Means Suppress 
13-END/13-LPH assay ACTH-assay Cortisol assay 
Subject 
n~..,~. De Post De  Post Pre Post 
#1 ! . i 6  !.27 2.15 2.38 1.61 1.00 
+ 0.37 + 0.56 + 0.24 + 0.26 + 0.37 + 0,26 
( + )  ( + )  ( - )  
#2  2.23 1.91 2.5; 2.61 13.56 9.02 
-:,).4 +0 .3  + 0.3~', +0.28 +3.75 + 1.13 
(+) t+) (+) 
#3 2.29 1.56 2.95 2. ! 6.84 1.42 
+0.18 +0 .3  +0 .06  +0.3  +0.96 +0.73 
( - )  ( - )  ( - )  
# 4  2.24 2.18 2.38 1.98 3.02 0.73 
+ 1.0 +0.65 +0.35 +0.3  +0.39 +0.26 
(+) (+) t - )  
#5  1.51 1.92 2.43 2.38 6.90 2.59 
+0.13 +0.31 +0 .26  +0.46 + 1.33 +0.53 
(+) (+) ( - )  
Subjects #1, #2 and #4 were MDD, #3 was a psychiatric control, and #5 was in a drug abuse group. ( + ) Means escape and ( - ) means suppression. 
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levels in all three groups. However, the peptide de- 
crease in MDD patients is less pronounced than in the 
controls (radio [3-END/[3-LPH postdex: [3-END/[3-LPH 
predex = 26% for normal controls, 39% for psychiatric 
controls, 74% for MDD subjects). Finally, these data 
suggest that POMC proddcts are hypersecreted by MDD 
patients at rest, at least for the 4 PM time period relative 
to normals, but not relative to psychiatric controls (MDD: 
3.16 --. 0.42 fmolc/ml; Controls: 1.8 --- 0.19 fmoles/ml; 
Psychiatric Controls: 2.79 --+ 0.3). This rep~sents a 75% 
increase over normals, but only a 13% elevation relative 
to psychiatric controls. 
The Effect of Individual Variables in the Response 
to Dexamethasone 
In spite of the fact that approximately two-thirds of the 
MDD patients showed a lack of suppression of HPA func- 
tion following the dexamethasone challenge, our results 
again showed evidence of heterogeneity among the sub- 
jects. One-third appeared to have normal suppressive re- 
sponses to dexamethasone with both assays, and a number 
of subjects were nonsuppressiv6 with only one of the two 
hormonal measures. To further explore the source of such 
heterogeneity, we examined the effects of a number of 
variables including weight loss, severity of the depression, 
age and sex on both baseline measures and postdex re- 
sponses. Our results showed that the effects of weight 
change on the outcome were small, and that severity may 
contribute, but only modestly, to basal and postdexame- 
thasone levels, as detailed in a separate report Meador- 
Woodruff et al 1987). Therefore, we focused on the effects 
of age and sex on the HPA profiles of our subjects. 
E F F E C T  O F  A G E  A N D  S E X  O N  R E S T I N G  H O R M O N E  L E V -  
E L S  AND POST-DEX RESPONSES. There was only a minor 
correlation between age and resting cortisol when all sub- 
jects (MDD and control, men and women) were combined: 
r = 0.31. The overall correlation of age with resting [3- 
END/I3-LPH is r = 0.18. However, when the MDD pa- 
tients with HDRS > 15 (n = 28) were entered alone into 
a best-fit analysis, a two component function emerged (not 
shov, ,,;, demonstrating a major positive correlation begin- 
ning only around 40-45 years of age. Indeed, the corre- 
lation coefficient between age and resting cortisol from 
the age of 45 onward is r = 0.47 (p < 0.5) for both men 
and women (n = 18) (Figure 2). However, there was an 
obvious gender difference relative to this correlation with 
the males not fitting well. On the other hand, the corre- 
lation coefficient becomes quite substantial when MDD 
females over 45 are considered alone (n = 15, r = 0.69 
p < 0.01). Thus, in that subgroup of female depressive 
over 45, age accounted for 48% of the variance of resting 
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Figure 2. Age versus basal cortisol in E.D. patlents over 45 
years o.ld. 
On the other hand, the MDD patients showed an in- 
verted curvilinear two-component function when corre- 
lating resting [3-END/[3-LPH with age regardless of sex 
(not shown). After 45 years of age, there was a signif- 
icant negative correlation of resting [3-END/[3-LPH with 
age (r  = - 0 . 5 4 ,  n = 18, p < 0.02), which was true 
in both men and women (Figure 3). 
These results suggest that in MDD patients over 45 
years of age, resting cortisol increases with age. This pat- 
tern is particularly clear in women over the age of 45 as 
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Figure 3. Age versus mean basal 13-endorphin in E.D. patients 
over 45 years old. 
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variance. On the other hand, premenopausal women ap- 
pear more variable than men. Furthermore, aging is also 
accompanied by a decrease in ~-END/I3-LPH resting lev- 
els, possibly because of the negative feedback effect of 
the high cortisol levels on the anterior lobe corticotrophs, 
with this accounting for approximately 30% of :he ; ,ar i -  
ante.  
AGE AND POSTDEX CORTISOL AND [~-END/~-LPH. If 
age is correlateo with increased basal cortisol after age 45, 
how does age affect subsequent responsiveness to dexa- 
methasone? There appears to be a clear relationship, which 
can be seen in a number of ways. For instance, we com- 
pared the age of DST nonsuppressor and DST suppressor 
patients across three groups of MDD patients---the current 
University of Michigan MDD subjects (HDRS > 15, n 
= 28), the Henry Ford Group (reported in Matthews et 
al 1986, n = 16), and a separate group of subjects in the 
University of Michigan data base studied by Carroll and 
collaborators for whom cortisol was measured both pred- 
examethasone and postdexamethasone (n = 26). Across 
these 70 MDD subjects, there were 31 nonsuppressors, 
and 39 suppressors; the mean age for DST cortisol non- 
suppressor patients was 12 years higher than the mean age 
for DST suppressors (58.4 versus 46.4, with an overall 
mean of 52).  
Figure 4 and Table 4 show a different way of analyzing 
the interaction between resting hormone levels, age, and 
the likelihood of being nonsuppressive with dexametha- 
sone. Figure 4 depicts resting steroid and peptide levels 
for the University of Michigan group; the domain outlined 
by the dashed rectangle delineates the "normal domain" 
of resting values, that is, range of predexamethasone val- 
ues found in 95% of the control subjects. Thus, over 95% 
of our controls had 4 PM basal cortisol values below 13 
~g/dl and basal 13-END/~-LPH values below 4.5 fmoles/m!. 
As can be seen from Figure 4, a number of the MDD 
patients were outside this normal domain. In particular, 
six subjects had unusually high cortisol levels (i.e. > 13 
p,g/dl). These subjects were 100% positive on the DST 
with the cortisol assay, and 66% positive on the I3-END/I3- 
LPH assay. Interestingly, their mean age is 65.0 _ 3.0. 
On the other hand, the group that had a normal cordsol 
predex, had only a 5% rate of incidence of DST abnor- 
mality with the cortisol assay and a mean age of 45.4 
(Table 4). Thus, if a subject has high basal cortisol, the 
chances are good that he/she also is both older and a DST 
nonsuppressor. 
That this observation may have some general validity 
can be seen from the second part of Table 4, showing 
the same analysis for the previously described Henry Ford 
Hospital group. Here again, subjects with high resting 
cortisol (> 13 p,g/dl) have a 100% chance of being a 
DST nonsuppressor on both cortisol and J3-ENDq3-LPH 
assays, and are older than subjects with lower resting 
cortisol (61.8 +- 4.1 versus 50.4 _+ 4.5). 
Thus, there is a complex interaction between age, rest- 
ing cortisol level, and DST nonsuppression. The effect of 
age on I3-END/13-LPH abnormality is not quite as evident. 
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Figure 4. Mean basal 13-endorphin versus 
mean basal cortisol in E.D. patients. 
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Table 4. Cortisol Resting Levels versus Age in MDD 
(Studies 1 & 2) 
University of  Michigan Subjects 
Normal resting level: < 13 at 4 Hi Resting Levels: 
PM > 13 at 4 PM 
n = 22 
X Age: 45.36 ± 3.3 
p~ede~ ~,ot-i = 7.73 ± 0.62 
postdex cort = 1.57 ± 0.27 
9o Cort positive = 1/22 = 5% 
% 13E "nonsuppressor" = 12/22 
= 54% 
n = 6  
X Age:  65 ± 3.0 ~ 
predex c o r t =  18.2 ± 1.74 
postdex cort = 9.6 -- 0.66 
% Cort  posit ive = 6/6 = 100% 
% 13E "nonsuppressox" = 4/6 
= 66% 
Hem3, Ford Subjects 
Normal resting levels: 
< 13 at 4 PM Hi resting levels: > 13 at 4 PM 
n = 9  
X Age = 50.4 ± 4.5 
predex cort = 8.36 ± 1.13 
postdex c o r t =  4.29 ± 1.09 
% Cort positive = 4/9 = 44% 
% 13E "nonsuppressor"  = 5/9 
= 56% 
n = 5  
X Age  = 61.8 -4- 4.14 
predex cort = 16.38 ± 2.1 
~' postdex cort = 16.68 ± 3.55 
% Cort  posit ive = 5/5 = 100% 
% 13E "nonsuppressor"  = 5/5 
= 100% 
oSignificantly different from "normal resting levels" group---p < 0.02. 
at rest. Because of negative-feedback mechanisms, high 
cortisol often leads to normal or low I~-END/13-LPH levels, 
which renders the analysis of that variable more difficult 
(note in Figure 4 the absence of any subjects high on both 
I3-END/I3-LPH and cortiso!). 
Discussion 
The present study permits a number of conclusions, which 
extend our previous findings reported by Matthews et al 
(1986). Firstly, the data confirm our results which showed 
that MDD patients have only mildly elevated basal levels 
of 13-END/I~-LPH at 4 PM compared to psychiatric con- 
trois, although they exhibit a 75% elevation over normal 
controls. Yet, as a group, the MDD subjects show de- 
creased suppression to dexamethasone in comparison to 
either control group. Secondly, our findings support the 
usefulness of employing an individual rather than group 
criterion for abnormal peptide responsiveness to dexa- 
methasone (e.g., the "overlap of the SEM" criterion). This 
criterion is further validated by the use of a normal (non- 
psychiatric) control group including both men and women 
with an age range of 20 to 68, all of whom suppressed by 
the overlap criterion. Thirdly, the 13-END/13-LPH assay 
continues to detect, as nonsuppressors, a number of sub- 
jects not detected by the cortisol assay. In addition, as 
shown in a small group of patients, this does not appear 
to be caused by a dissociation between ACTH and 13- 
END/I3-LPH responsiveness, as these two peptides appear 
to change in synchrony. Rather, the dissociation appears 
to be caused by the different regulatory mechanisms at the 
level of the pituitary corticotroph versus the adrenal cortex. 
Fourthly, the combination of the two assays, following 
dexamethasone, that is, [3-END/I3-LPH and co,so!,  ~ows 
about two-thirds of MD patients to be nonsuppressors, 
whereas psychiatric controls exhibit an 18% rate of non- 
suppression on the combined measures, and normal con- 
trois have a 0% rate of nonsuppression. The low rate of 
nonsuppression in our normal control subjects relative to 
the 5%-10% reported in the literature (Arana et al 1985) 
may be due to our use of catheters followed by a rest 
period, which insures minimal stress at the time of blood 
collection. 
In addition, the present study examines some of the 
possible sources of variance between subjects in terms of 
neuroendocrine profile. Given that they all carry the same 
diagnosis, MDD, and are "in episode," why are some 
abnormal on one HPA axis measure, some on both mea- 
sures, and some on neither? A major factor appears to be 
the interaction of hormonal basal and postdexamehhasone 
levels with both age and sex. The age plays an important 
role in determining basal and postdexamethasone cortisol 
levels has been previously documented (Halbreich et al 
1984; Oxenkrug et al 1983; Lewis et al 1984; Alexopoulos 
et al 1984). In particular, basal cortisol levels are highly 
positively correlated with age in older (over 45) females, 
accounting for 48% of the variance in this particular sam- 
ple. I3-END/[3-LPH levels are negatively correlated with 
age, suggesting generally intact negative feedback of the 
resting cortisol levels upon [~-END/I3-LPH secretion. If an 
older female has abnormally high cortisol, she has an ex- 
tremely good chance of being found DST nonsuppressive 
on the cortisol assay, that is, failing to suppre-s below the 
5 ttg/dl cut-off. This does not, however, indicate a system 
completely insensitive to negative feedback, as such a 
patient often will decrease cortisol secretion postdexa- 
methasone, but not to normal levels. These older patients 
may truly have developed adrenal hyperplasia. In addition, 
they may have slightly altered set points to negative steroid 
feedback either at the limbic or pituitary level, resulting 
from chronically elevated steroid levels. It should be noted 
here that aging in nondepressed females does not lead to 
significant changes in resting cortisol levels at any time 
of the day (Tinngco et al 1986). It also should be noted 
that aged depressives tend -to hart, hig~,~r severity ratings 
and have had more episodes of depression. Thus, this 
relationship between age, sex, and basal cortisol may be 
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due to the interaction of these factors with some aspect of 
the depressive illness (chronic stress, predisposing factors, 
drug history, etc.). Although our own sample is relatively 
small, a recent report by Maes et al (1990) supports these 
conclusions. Their data suggested that 54% of the variance 
in postdex cortisol could be explained by baseline cortisol 
secretion as assessed by urinary free cortisol, age, and 
dexamethasone plasma levels, independent of depressed 
mood. 
Although the prototypical depressed, aged female with 
high basal cortisol is easily detected by the classical DST 
and to some extent by the 13E assay, the other patients 
are more difficult to characterize, particularly those who 
are normal on postdexamethasone cortisol but abnormal 
on []-END/I3-LPH. A subject with resting cortisol close 
to the 5 p,g/dl cut-off can suppress very little and still be 
termed a suppressor if he goes below the cut-off. On the 
other hand, the i3-END/~-LPH response, as structured with 
the overlap method, may detect an abnolmality in such 
a subject. Thus, part of the discrepancy between the two 
tests may derive from the different criteria for an "ab- 
normal" response. Recent studies suggest that lower plasma 
dexamethasone levels in DST nonsuppressor patients may 
be responsible for some of the DST co~iso! nonsuppres- 
sion (Morris et al 1986; Maguire et al 1987; Wiedeman 
and Holsboer 1977; Johnson et al 1984; Meikle 1982). 
In this current study we do not have plasma dexameth- 
asone levels. However, it is probable that a number of 
these depressed elderly patients with hypercortisolinemia 
may have low plasma dex levels that account for the cor- 
tisol nonsuppression. Whether lower plasma de.x leveis 
are responsible for the {~-END/J3-LPH in these patients 
is not clear. Data from a different group of depressed 
patients studied by our group (Young et al 1992) does 
not demonstrate a difference in plasma dexamethasone 
levels between 13-END/I3-LPH suppressors and nonsup- 
pressors. 
At a more conceptual level, we need to consider the 
issue of an abnormal 13-END/J3-LPH response to dexa- 
methasone in the face of a cortisoi response that falls within 
a typically normal domain. How can one not respond to 
dexamethasone at the pituitary and suprapituitary level and 
yet continue to exhibit an apparently normal adrenal 
suppression? One possibility is that temporal considera- 
tions and differences in half-life of the hormones might 
be confounding results. Specifically, [3-END/[8-LPH val- 
ues may show escape from dexamethasone suppression 
first, followed by a cortisol escape. Because we assess the 
full endocrine profile only at one time (3:30-4:30 aM) we 
may be missing the later stages of such a temporal pat- 
terning. We have conducted a separate study to examine 
this possibility, testing our subjects at different times of 
the day. Our results (Young et al 1992) have shown that 
4 PM is in fact, the best time to detect escape from dex- 
amethasone for both the peptide and the glucocorticoids. 
Thus, time of day does not appear to explain the disso- 
ciation between cortisol and J3-END/I3-LPH results. An 
alternative and more intriguing explanation is that there 
may be previously ignored negative feedback mechanisms 
at the le,,el of the adrenal itself (Black et al 1961). In other 
words, dexamethasone could cause adrenal inhibition of 
steroidogenesis beyond its effects on the pituitary and lim- 
bic system (Carsia et al 1982). It is conceivable that in 
some subjects, dexamethasone suppression at the pituitary 
and suprapituitary levels becomes less effective, whereas 
effects at the adrenal levels are maintained. 
Finally, we need to consider subjects with depression 
but with normal resting values of [3-END/I3-LPH and cor- 
tisol, and a normal response oi both hormones to dexa- 
methasone. In other words, these subjects appear to have 
a normal HPA axis both at rest and following steroid chal- 
lenge. They constitute approximately 35% of our popu- 
lation (14 out of 39). Interestingly, men are overrepre- 
sented in this group (50% of the men and 28% of the 
women are . . . . . .  in thi~ c,--~'nun~l-,- The mean_ age of this group 
(48.4 _ 4.9) is not significantly different from the gener~ 
mean, and the group Hamilton score (17.0 +_ 2.3) is only 
slightly lower than the overall Hamilton (19.46 +_ 1.9). 
However, severity may play a role in whether a subject 
has a completely normal endocrine profile. A patient with 
a Hamilton score greater than 25 has only a 27% chance 
of being normal on the combined criteria, compared to 
35% for those with HRSD scores of 15 to 24, and 56% 
for those with HRSD scores below 15. 
It is therefore apparent that within the spectrum of en- 
dogenous depression, multiple endocrine profiles do emerge, 
which interact with the subjects' age, sex, and current 
severity of depression. An important issue for further con- 
sideration is whether the number of prc;'ious episodes con- 
tributes to the endocrine profile. In general, one can con- 
ceive of these unusual patterns as reflective of multiple 
regulatory strategies of the HPA axis in response to unusual 
neuronal, hormonal, or environmental demands on that 
system. Given the flexibility of the HPA system and the 
multiplicity of its checks and balances, it is perhaps not 
unexpected that multiple patterns of responses appear to 
emerge across patients. 
This work :,,as sl,~ported in part by NIMH grant #MH42251 (S.J. Wat- 
son and H. Akil); NIMH RSDA #MH00427 (E. Young); NIMH grant 
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of Michigan (NIMH #RR00042); and the Department of Psychiatry. 
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